2-溴-3-硝基-5-甲基吡啶 | 23056-46-4

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 中文名称: 2-溴-3-硝基-5-甲基吡啶
• 中文别名: 2-溴-5-甲基-3-硝基吡啶；2-溴-3-硝基-5-甲基嘧啶
• 英文名称: 2-bromo-5-methyl-3-nitropyridine
• CAS: 23056-46-4
• 化学式: C₆H₅BrN₂O₂
• 分子量: 217.022
• InChiKey: AESPBTFGZRRYRJ-UHFFFAOYSA-N

物化性质

• 沸点：
  276.7±35.0 °C(Predicted)
• 密度：
  1.709±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  58.7
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26
• 危险类别码：
  R20/21/22
• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  | 温度范围：2-8℃ |

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Bromo-5-methyl-3-nitropyridine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Bromo-5-methyl-3-nitropyridine
CAS number: 23056-46-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H5BrN2O2
Molecular weight: 217

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-溴-3-硝基-5-甲基吡啶 在 甲醇 、 N-溴代丁二酰亚胺(NBS) 、 偶氮二异丁腈 、 氢气 、 三乙胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 四氯化碳 为溶剂， 20.0~130.0 ℃ 、101.33 kPa 条件下， 反应 6.0h， 生成 (S)-tert-butyl 3-((2-bromo-5-((2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)methyl)pyridin-3-yl)carbamoyl)pyrrolidine-1-carboxylate
  参考文献：
  名称：

  新的喹唑啉-2,4（1 H，3 H）-二酮衍生物作为有效的PARP-2选择性抑制剂的发现

  摘要：

  PARP-2选择性抑制剂对于阐明PARP-2在病理生理过程中的特定作用以及开发具有减少脱靶副作用的所需药物非常重要。在这项工作中，设计并合成了一系列新颖的喹唑啉-2,4（1 H，3 H）-二酮衍生物，以探索同工型选择性PARP抑制剂。结果，化合物11a（PARP-1 IC 50  = 467 nM，PARP-2 IC 50  = 11.5 nM，选择性PARP-1 / PARP-2 = 40.6）被公开为最具选择性的PARP-2抑制剂，对日期。化合物11a的结合特征 分别研究了PARP-1和PARP-2中的CPA内含子，以为进一步利用CDOCKER程序构建PARP-1和PARP-2的同工型选择性抑制剂提供有用的见解。

  DOI：

  10.1016/j.bmc.2017.05.052
• 作为产物：
  描述：

  5-甲基-2-氨基-3-硝基吡啶 在 氢溴酸 、 溴 、 sodium nitrite 、 sodium hydroxide 作用下， 以 水 为溶剂， 反应 2.0h， 以28%的产率得到2-溴-3-硝基-5-甲基吡啶
  参考文献：
  名称：

  WO2006/76644

  摘要：

  公开号：

文献信息

• [EN] SPIRO-SUBSTITUTED OXINDOLE DERIVATIVES HAVING AMPK ACTIVITY<br/>[FR] DÉRIVÉS D'OXINDOLE SPIRO-SUBSTITUÉS AYANT UNE ACTIVITÉ SUR AMPK
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2014202580A1

  公开（公告）日：2014-12-24

  The present invention relates to compounds of formula (I), which have valuable pharmacological properties, in particular are activators of AMPK and which are therefore useful in the treatment of certain disorders that can be prevented or treated by activation of this receptor. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

  本发明涉及具有有价值的药理特性的式(I)化合物，特别是AMPK激活剂，因此在治疗某些可以通过激活该受体预防或治疗的疾病方面具有用处。这些化合物适用于治疗和预防可以受该受体影响的疾病，如代谢性疾病，特别是2型糖尿病。
• Validation of Phosphodiesterase-10 as a Novel Target for Pulmonary Arterial Hypertension via Highly Selective and Subnanomolar Inhibitors
  作者：Yi-You Huang、Yan-Fa Yu、Chen Zhang、Yiping Chen、Qian Zhou、Zhuoming Li、Sihang Zhou、Zhe Li、Lei Guo、Deyan Wu、Yinuo Wu、Hai-Bin Luo

  DOI：10.1021/acs.jmedchem.9b00224

  日期：2019.4.11

  phosphodiesterase-10 (PDE10) was reported to be a promising target for PAH based on the studies with a nonselective PDE inhibitor papaverine, but little progress has been made to confirm the practical application of PDE10 inhibitors. To validate whether PAH is ameliorated by PDE10 inhibition rather than other PDE isoforms, here we report an integrated strategy to discover highly selective PDE10 inhibitors as chemical

  肺动脉高压（PAH）导致肺血管阻力的病理性增加，导致右心衰竭和最终死亡。以前，基于对非选择性PDE抑制剂罂粟碱的研究，据报道磷酸二酯酶10（PDE10）是PAH的有希望的靶标，但在确认PDE10抑制剂的实际应用方面进展甚微。为了验证PAH是否可通过PDE10抑制而不是其他PDE亚型得到改善，在此我们报告了一项综合策略，以发现高选择性PDE10抑制剂作为化学探针。结构优化产生了PDE10抑制剂2b，具有亚纳摩尔亲和力和对其他PDE的> 45,000倍的良好选择性。PDE10-2b配合物的共晶体结构显示2b和Tyr693之间重要的H键相互作用。最后，化合物2b显着降低了PAH大鼠的动脉压，因此验证了PDE10作为新型抗PAH靶标的潜力。这些发现表明，PDE10抑制可能是PAH的可行治疗选择。
• [EN] NEW 6-MEMBERED HETEROAROMATIC SUBSTITUTED CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS<br/>[FR] NOUVEAUX DÉRIVÉS DE CYANOINDOLINE À SUBSTITUTION HÉTÉROAROMATIQUE À 6 CHAÎNONS UTILISÉS COMME INHIBITEURS DE NIK
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2017125534A1

  公开（公告）日：2017-07-27

  The present invention relates to pharmaceutical agents of formula (I), useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-KB-inducing kinase (NIK - also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.

  本发明涉及公式（I）的药物制剂，用于治疗和/或预防哺乳动物，特别是用于治疗癌症、炎症性疾病、代谢性疾病和自身免疫性疾病的NF-KB诱导激酶（NIK - 也称为MAP3K14）抑制剂。该发明还涉及包含这些化合物的药物组合物，以及利用这些化合物或药物组合物预防或治疗癌症、炎症性疾病、包括肥胖和糖尿病在内的代谢性疾病以及自身免疫性疾病的用途。
• [EN] NITROGEN HETEROCYCLIC COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES AZOTÉS ET LEURS MÉTHODES D'UTILISATION
  申请人：BLACK DIAMOND THERAPEUTICS INC

  公开号：WO2021127397A1

  公开（公告）日：2021-06-24

  The present disclosure relates to compounds of formula (I): and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparing the compounds, compositions comprising the compounds, and methods of using the compounds as inhibitors of receptor tyrosine kinases, in particular oncogenic mutants of ErbB-receptors e.g. in the treatment of cancer.

  本公开涉及式(I)的化合物，以及其药学上可接受的盐和立体异构体。本公开还涉及制备这些化合物的方法，包含这些化合物的组合物，以及将这些化合物用作受体酪氨酸激酶的抑制剂的方法，特别是ErbB受体的致癌突变体，例如在癌症治疗中的应用。
• [EN] FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESUFLONAMIDES AS CCR2 MODULATORS FOR THE TREAMENT OF INFLAMMATION<br/>[FR] HÉTÉROARYL-PYRIDYL- ET PHÉNYL-BENZÈNESULFONAMIDES CONDENSÉS EN TANT QUE MODULATEURS DU CCR2 POUR LE TRAITEMENT DE L'INFLAMMATION
  申请人：CHEMOCENTRYX INC

  公开号：WO2009009740A1

  公开（公告）日：2009-01-15

  Compounds are provided that act as potent antagonists of the CCR2 receptor. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2- mediated diseases and as controls in assays for the identification of CCR2 antagonists. A compound of the formula (I) or a salt thereof: where: R1 and R2 are each independently hydrogen, halogen, C1-8alkyl, -CN. or C1-8 haloalkyl, provided that at least one of R11or R2 is other than hydrogen; each R3 is independently hydrogen; R4 is hydrogen; R5 is halogen or C1-8 alkyl; R6 is hydrogen; X1 is CR7, N or NO; X2 and X4 are N or NO; X3 is CR7; X6 and X7 are each independently selected from CR7, N, and NO; each R7 is independently selected from the group consisting of hydrogen, halogen, substituted or unsubstituted C2-8 alkyl, substituted or unsubstituted C2-8 alkeπyl, substituted or unsubstituted C2-8 alkynyl, -CN. =O, -NO2, -OR6, -OC(O)R8, -CO2R8, -C(O)R8, -C(O)NR0R8, -OC(O)NR9R8, -NR10C(O)R8, -NR10C(O)NR9R8, -NR9R8, -NR10CO2R8, -SR8, -S(O)R8, -S(O)2R8, -S(O)2NR9R8, -NR10S(O)2R8, substituted or unsubstituted C6-10 aryl, substituted or unsubstituted 5- to 10-membered heteroaryl and substituted or unsubstituted 3- to 10-membered heterocyclyl;

  提供的化合物作为CCR2受体的有效拮抗剂。这些化合物通常是芳基磺酰胺衍生物，可用于制药组合物、治疗CCR2介导疾病的方法以及作为鉴定CCR2拮抗剂的测定中的对照物。具有以下式（I）或其盐的化合物：其中：R1和R2各自独立地是氢、卤素、C1-8烷基、-CN或C1-8卤代烷基，但至少其中一个是氢以外的；每个R3独立地是氢；R4是氢；R5是卤素或C1-8烷基；R6是氢；X1是CR7、N或NO；X2和X4是N或NO；X3是CR7；X6和X7各自独立地选自CR7、N和NO；每个R7独立地选自氢、卤素、取代或未取代的C2-8烷基、取代或未取代的C2-8烯基、取代或未取代的C2-8炔基、-CN、=O、-NO2、-OR6、-OC（O）R8、-CO2R8、-C（O）R8、-C（O）NR0R8、-OC（O）NR9R8、-NR10C（O）R8、-NR10C（O）NR9R8、-NR9R8、-NR10CO2R8、-SR8、-S（O）R8、-S（O）2R8、-S（O）2NR9R8、-NR10S（O）2R8、取代或未取代的C6-10芳基、取代或未取代的5-至10-成员杂芳基和取代或未取代的3-至10-成员杂环烷基。